Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-EN Version v5-FR
Language English French
Date Updated 2022-03-19 2022-01-21
Drug Identification Number 02242905 02242905
Brand name MIDAZOLAM INJECTION MIDAZOLAM INJECTION
Common or Proper name Midazolam Injection 5 mg/mL MD Vial 10 mL Midazolam Injection 5 mg/mL MD Vial 10 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients MIDAZOLAM MIDAZOLAM
Strength(s) 5MG 5MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 10 mL 10 mL
ATC code N05CD N05CD
ATC description HYPNOTICS AND SEDATIVES HYPNOTICS AND SEDATIVES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2022-01-01 2022-01-01
Actual start date
Estimated end date 2022-03-18 2022-03-04
Actual end date 2022-03-18
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Midazolam Injection 5 mg/mL MD Vial 10 mL effective January 1, 2022 until January 31, 2022. Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Midazolam Injection 5 mg/mL MD Vial 10 mL effective January 1, 2022 until January 31, 2022.
Health Canada comments